Lilly stockpiles $1.5 billion of orforglipron ahead of FDA decision

Eli Lilly reported about $1.5 billion in pre-launch inventory of orforglipron, its experimental oral weight-loss pill, as of Dec. 31, according to a securities filing disclosed on Feb. 12. A year earlier, the company had nearly $550 million in pre-launch inventory tied to the pill, making the new figure nearly three times as large. ^[1][2]

Most of the inventory is tied to orforglipron, Lilly said in the filing. ^[2] It is common for drugmakers to build supplies before an expected approval, and companies include those assets in their financial statements to show how much product has been manufactured ahead of a decision. ^[1]

The stockpile was built ahead of an expected US Food and Drug Administration decision on the pill, which is now targeted for April 10. ^[1][2] Orforglipron received an FDA Commissioner's National Priority Voucher in November, a designation that can shorten review times to as little as one to two months, compared with the typical 10 to 12 months for most new medicines. ^[1][2] The FDA later pushed its target decision date out to April. ^[2] The voucher program has drawn pushback from lawmakers who question whether it could erode the agency's review standards. ^[2]

FiercePharma reported that the early and aggressive stockpiling suggests Lilly is trying to avoid a repeat of the supply shortages that followed the launches of its injectable drugs Mounjaro and Zepbound. ^[2] Those shortages helped create a market for compounded versions of GLP-1 drugs that has been difficult to rein in, the publication reported. ^[2] Lilly has previously said it is confident it will have enough supply to launch the weight-loss pill in several countries nearly simultaneously if it wins approval. ^[1]

At the J.P. Morgan Healthcare Conference in January, Lilly's chief scientist, Daniel Skovronsky, said the company planned to launch orforglipron "in many, many countries around the world, as quickly as possible," according to Reuters. ^[2]

If approved, orforglipron would compete with Novo Nordisk's once-daily Wegovy pill, which the FDA approved in late December and which launched in the US in early January. ^[1][2] Prescriptions for that pill topped 26,000 in the second full week after launch, according to IQVIA data shared by an analyst. ^[1]

Lilly has not disclosed a US price for orforglipron, and the FDA has not yet decided whether to approve it.

Why it matters for patients

Both Wegovy and Zepbound are injections, so an approved oral GLP-1 would add an option that does not require a shot. For people who have trouble with injections, that difference can shape which treatment they can use.

The stockpile is also a response to a problem patients have already lived through. When Mounjaro and Zepbound launched, supplies ran short, and some patients turned to compounded versions of GLP-1 drugs because they could not find the brand-name product. ^[2] Lilly's buildup suggests it is trying to have product ready on day one. ^[2]

A stockpile, however, does not guarantee that a pharmacy will have the pill in stock, and it does not guarantee that the FDA will approve it. Pricing and insurance coverage have not been disclosed in these reports. For most patients, whether a plan covers a new obesity drug matters as much as whether it is available.

What happens next

• April 10, 2026: the FDA's target date for a decision on orforglipron. ^[2]
• If approved, Lilly has said it plans to launch the pill in many countries as quickly as possible. ^[2]

The US price, insurance coverage and how quickly the pill would reach pharmacies have not been reported.